Panevezio Statybos Lt 1 Stock
Price
Target price
-
-
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Panevezio Statybos Lt 1 in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Panevezio Statybos Lt 1 vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Panevezio Statybos Lt 1 | - | - | - | - | - | - | - |
| J+p-Avax S.a. Nam. Eo 0,58 | 4.870% | 0.452% | -1.767% | 58.810% | 52.283% | 166.374% | 304.242% |
| Verbrec Ltd. | 0.000% | 9.189% | -0.980% | 248.276% | -11.404% | 108.247% | 42.254% |
| Inypsa | -1.660% | 1.954% | 8.568% | -18.173% | 5.595% | 14.010% | -16.792% |
News
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
Key Points
- Interested in Bicara Therapeutics Inc.? Here are five stocks we like better.
- Bicara Therapeutics said new ASCO data support ficerafusp alfa in first-line recurrent or metastatic
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data
Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its
Bicara Therapeutics Q1 Earnings Call Highlights
Bicara Therapeutics (NASDAQ:BCAX) said it made progress during the first quarter of 2026 on the development and commercialization strategy for its lead drug candidate, ficerafusp alfa, or FICERA